Marco Fiore

Prof. Dr. Marco Fiore

GENERAL AND SPECIALIZED SURGERY FOR WOMEN AND CHILDREN, Azienda Ospedaliera Universitaria Università degli Studi della Campania Luigi Vanvitelli, Naples, Campania, Italy
orcid

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 January 2020 in Mycoses
Verified
Journal Article
Closed access
PDF file
Daniele Roberto GiacobbeDaniele Roberto Giacobbe
Daniele Roberto Giacobbe
Alberto MaraoloAlberto Maraolo
Alberto Maraolo
VSVittorio Simeon
Vittorio Simeon
FMFederica Magnè
Federica Magnè
MPMaria Caterina Pace
Maria Caterina Pace
MBMatteo Bassetti
Matteo Bassetti

7 July 2020 in Antibiotics
Verified
Journal Article
Open access
PDF file
Marco FioreMarco Fiore
Marco Fiore
Aniello AlfieriAniello Alfieri
Aniello Alfieri
SFSveva Di Franco
Sveva Di Franco
Maria Caterina PaceMaria Caterina Pace
Maria Caterina Pace
VSVittorio Simeon
Vittorio Simeon
Andrea CortegianiAndrea Cortegiani
Andrea Cortegiani
Ceftazidime-avibactam (CZA) is a novel beta-lactam beta-lactamase inhibitor combination approved for the treatment of complicated urinary tract infections, complicated intra-abdominal infections, and for hospital-acquired/ventilator-associated pneumonia. The aim of this systematic review (PROSPERO registration number: CRD42019128927) was to evaluate the effectiveness of CZA combination therapy versus CZA monotherapy in the treatment of severe infections. The databases included in the search, until 12 February 2020, were MEDLINE by PubMed, EMBASE, and The Cochrane Central Register of Controlled Trials. We included both randomized controlled trials (RCTs) and non-randomized studies published in peer-reviewed journals and in the English language. The primary outcome was all-cause mortality (longest follow-up) evaluated in patients with the diagnosis of infection with at least one pathogen; secondary outcomes were clinical and microbiological improvement/cure. Thirteen studies were included in the qualitative synthesis: 7 RCTs and 6 retrospective studies All the six retrospective studies identified carbapenamase-producing Enterobacteriaceae (CRE) as the cause of infection and for this reason were included in the network meta-analysis (NMA); the quality of the studies, assessed using the New Castle-Ottawa Scale, was moderate-high. In all the six retrospective studies included in the NMA, CZA was used in large part for off-label indications (mostly blood stream infections: 80–100% of patients included). No difference in mortality rate was observed in patients undergoing CZA combination therapy compared to CZA monotherapy [n = 503 patients, direct evidence OR: 0.96, 95% CI: 0.65–1.41].

1 January 2018 in BioMed Research International
Verified
Journal Article
Open access
PDF file
Marco FioreMarco Fiore
Marco Fiore
SLSebastiano Leone
Sebastiano Leone
Alberto MaraoloAlberto Maraolo
Alberto Maraolo
EBEmilio Berti
Emilio Berti
Giovanni DamianiGiovanni Damiani
Giovanni Damiani
Psoriasis is a chronic inflammatory disease of the skin affecting approximately 2% of the world’s population. Systemic treatments, including methotrexate and cyclosporin, are associated with potential hepatotoxicity, due to either direct liver damage or immunosuppression or both immunomediated and a direct liver injury; therefore, treatment of patients with psoriasis poses a therapeutic challenge. The aim of this minireview is to help clinicians in the management of psoriatic patients who develop signs of liver dysfunction. To find relevant articles, a comprehensive search was performed on PubMed, EMBASE, and Cochrane with appropriate combinations of the following keywords being considered: viral hepatitis, nonalcoholic fatty liver disease, psoriasis, hepatotoxicity, drug toxicity, cholestasis, and autoimmune liver diseases.

23 August 2011 in Journal of Medical Virology
Verified
Journal Article
Closed access
PDF file
Nicola CoppolaNicola Coppola
Nicola Coppola
GTGilda Tonziello
Gilda Tonziello
MPMariantonietta Pisaturo
Mariantonietta Pisaturo
VMVincenzo Messina
Vincenzo Messina
SGSalvatore Guastafierro
Salvatore Guastafierro
ESEvangelista Sagnelli
Evangelista Sagnelli

28 October 2017 in World Journal of Hepatology
Verified
Journal Article
Open access
Marco FioreMarco Fiore
Marco Fiore
Alberto MaraoloAlberto Maraolo
Alberto Maraolo
IGIvan Gentile
Ivan Gentile
GBGuglielmo Borgia
Guglielmo Borgia
SLSebastiano Leone
Sebastiano Leone
MPMaria Caterina Pace
Maria Caterina Pace
Spontaneous bacterial peritonitis (SBP) is the most common infection in end-stage liver disease patients. SBP is defined as an ascitic fluid infection with a polymorphonuclear leucocyte count ≥ 250/mm3 without an evident intra-abdominal surgically treatable source. Several mechanisms contribute to SBP occurrence, including translocation of gut bacteria and their products, reduced intestinal motility provoking bacterial overgrowth, alteration of the gut's barrier function and local immune responses. Historically, Gram-negative enteric bacteria have been the main causative agents of SBP, thereby guiding the empirical therapeutic choice. However, over the last decade, a worryingly increasing prevalence of Gram-positive and multi-drug resistant (MDR) SBP has been seen. Recently, the microbiological spectrum of SBP seems to have changed in Europe due to a high prevalence of Gram-positive bacteria (48%-62%). The overall proportion of MDR bacteria is up to 22%-73% of cases. Consequently, empirical therapy based on third-generation cephalosporins or amoxicillin/clavulanic acid, can no longer be considered the standard of care, as these drugs are associated with poor outcomes. The aim of this review is to describe, with an epidemiological focus, the evidence behind this rise in Gram-positive and MDR SBP from 2000 to present, and illustrate potential targeted therapeutic strategies. An appropriate treatment protocol should include daptomycin plus ceftaroline and meropenem, with prompt stepdown to a narrower spectrum when cultures and sensitivity data are available in order to reduce both cost and potential antibiotic resistance development.

1 January 2017 in World Journal of Gastroenterology
Verified
Journal Article
Open access
Marco FioreMarco Fiore
Marco Fiore
Alberto MaraoloAlberto Maraolo
Alberto Maraolo
IGIvan Gentile
Ivan Gentile
GBGuglielmo Borgia
Guglielmo Borgia
SLSebastiano Leone
Sebastiano Leone
MPMaria Caterina Pace
Maria Caterina Pace
To systematically review literature upon aetiology of nosocomial spontaneous bacterial peritonitis (N-SBP) given the rising importance of multidrug-resistant (MDR) bacteria. A literature search was performed on MEDLINE and Google Scholar databases from 2000 to 15th of November 2016, using the following search strategy: “spontaneous” AND “peritonitis”. The initial search through electronic databases retrieved 2556 records. After removing duplicates, 1958 records remained. One thousand seven hundred and thirty-five of them were excluded on the basis of the screening of titles and abstract, and the ensuing number of remaining articles was 223. Of these records, after careful evaluation, only 9 were included in the qualitative analysis. The overall proportion of MDR bacteria turned out to be from 22% to 73% of cases across the studies. N-SBP is caused, in a remarkable proportion, by MDR pathogens. This should prompt a careful re-assessment of guidelines addressing the treatment of this clinical entity.